个人简历

1982年1月，本科毕业于四川医学院药学专业，获学士学位。 1982年1月～1988年8月，任华西医科大学药学院毒物分析和仪器分析教员、助教、讲师。 1993年7月，研究生毕业于华西医科大学药剂学专业，获理学博士学位。 1993年12月，任华西医科大学药学院药剂学副教授、副院长。 1997年9月，破格晋升药剂学教授，被聘为博士研究生导师。 1999年1月～2017年6月，任华西医科大学药学院（四川大学华西药学院）院长。 1999年1月～2005年12月兼任四川大学药物研究所所长。 1999年4月～2004年8月兼任中日合资四川华星中医药有限公司董事长。 2000年4月～2003年6月，兼任四川大学华西制药厂厂长、党总支书记。

研究领域

靶向药物与释药系统研究

近期论文

1. L. Guo, S. Luo, ZW Du, ML Zhou, PW Li, Y. Fu, X. Sun, Y. Huang, ZR Zhang*. Targeted delivery of celastrol by albumin nanoparticles to mesangial cells against glomerulonephritis. Nature Communications. 2017, DOI : 10.1038/s41467-017-00834-8. IF=12.124. 2. XY Wang, BW Qi, HF Su, JB Li, X. Sun, Q. He，Y. Fu*, ZR Zhang*. Pyrilamine-sensitive proton-coupled organic cation (H+/OC) antiporter for brain-specific drug delivery. Journal of Controlled Release. 2017,254:34-43. IF=7.786. 3. S. Luo, PW Li, S. Li, ZW Du, X. Hu, Y. Fu*, ZR Zhang*. N, N-Dimethyl tertiary amino group mediated dual pancreas- and lung-targeting therapy against acute pancreatitis. Molecular Pharmaceutics. 2017,14(5):1771- 1781. IF=4.440. 4. YC Zeng, S. LI, C. Liu, T. Gong, X. Sun, Y. FU*, ZR Zhang*. Soluplus® micelles for improving oral bioavailability ofscopoletin and their hypouricemic effect in vivo. Acta Pharmacol Sinca, 2017,38(3):424-433. IF=3.223. 5. ML Zhou, JB Li, CH Li, L.Guo, XY Wang, Q. He, Y. Fu*, ZR Zhang*. Tertiary amine mediated targeted therapy against metastatic lung cancer. Journal of Controlled Release, 2016;241:81-93. IF=7.705. 6. X. Song, ZY Wan, TJ Chen, Y. Fu, KJ Jiang, XL Yi, H. Ke, JX Dong, LQ Yang, L. Li, X. Sun, T. Gong*, ZR Zhang*. Development of a Multi-Target Peptide for Potentiating Chemotherapy by Modulating Tumor Microenvironment. Biomaterials, 2016.108:44-56. IF=8.557. 7. D. Zheng，X. Shuai，YP Li, P. Zhou, T. Gong, X. Sun, ZR Zhang*. Novel flurbiprofen derivatives with improved brain delivery: Synthesis, in vitro and in vivo evaluation. Drug Delivery，2016, 23(7):2183-2192, IF=6.402. 8. HF Su, Q. Lin, XY Wang, Y. Fu, T. Gong, X. Sun, ZR Zhang*. Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms. Acta Pharmacol Sinca, 2016;37:545-554. IF=3.223. 9. Y. Fu，Q. Lin , T. Gong, X. Sun, ZR Zhang*. Mechanistic Studies of a Renal Targeted Triptolide- Glucosamine Conjugate with Lower toxicity and Superior Attenuation of Ischemia/Reperfusion Injury in Rats. Acta Pharmacol Sinca, 2016;37:1467-1480. IF=3.223. 10.XW Wei*, S. Bin, ZY He, TH Ye, M. Luo, YX Sang, X. Liang, W. Wang, ST Luo, SY Yang, CY Gong, ML Gou, HX Deng, YL Zhao, HS Yang, CJ Zhao, L. Yang, ZY Qian, X. Sun, JH Han, CY Jiang, S. Zhang, M. Wu, ZR Zhang*. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response. Cell Research. 2015, 25:1-17. IF=15.606. 11.JB Li, JJ Zhang, Y. Fu, X. Sun, T. Gong, ZR Zhang*. Dual-specific targeting therapy mediated by a phenolic propanediamine moiety for local and systemic complications of acute pancreatitis. Journal of Controlled Release.2015,212:19-29.IF=7.786. 12.T. Zhang, Q. Peng, FY San, MX Wang, WQ Wu, T. Gong*, ZR Zhang*. Sustained delivery of peptides and proteins by high content phospholipids-based phase separation gel. Biomaterials. 2015,45:1-9. IF=8.557. 13.Q. Wang, PF Liu, Y. Sun, T. Gong, MJ Zhu, X. Sun, ZR Zhang*, YR Duan*. Preparation and properties of biocompatible PS-PEG/calcium phosphate nanospheres. Nanotoxicology. 2015, 9:190. IF=6.428. 14.Y. Cheng, BY Zhu, Y. Deng, ZR Zhang *. In Vivo detection of cerebral amyloid fibrils with smart dcm-based fluorescence probe. Analytical Chemistry. 2015, 87:4781-4787. IF=6.32. 15.YP Li, YY Zhou, JY Jiang; XY Wang, Y. Fu, T. Gong, X. Sun, ZR Zhang*. Brain-targeting mechanism of dexibuprofen prodrugs modified with ethanolamine-related structures. Journal of Cerebral Blood Flow and Metabolism. 2015, 35:1985-1994. IF=5.08. 16.JJ. Zhang, T. Gong*, ZR Zhang*. Mechanism of enhanced oral absorption of morin by phospholipid complex based self-nanoemulsifying drug delivery system. Molecular Pharmaceutics. 2015, 12:504-513. IF=4.440 17.Q. Lin, LQ Ling, L. Guo, JJ Zhang, T. Gong, X. Sun, ZR Zhang*. Molecular property and intestinal absorption characteristics of imperialinein vitro and in situ. Acta Pharmacologica Sinica. 2015,36:863-873. IF=3.223. 18.Q. Lin, Y. Fu, J. Li, MK Qu, L. Deng, T Gong*, ZR Zhang*. A (polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability. European Journal of Pharmaceutical Sciences. 2015,79:44-52. IF=3.756.